Top

Published in:

01-06-2012

Bronchoalveolar Lavage Total Cell Count in Interstitial Lung Diseases—Does It Matter?

Authors: Joanna Domagała-Kulawik, Tomasz Skirecki, Marta Maskey-Warzechowska, Hanna Grubek-Jaworska, Ryszarda Chazan

Published in: Inflammation | Issue 3/2012

Abstract

Bronchoalveolar lavage (BAL) is a useful technique for differential diagnosis of various interstitial lung diseases (ILDs) and is usually realized by analysis of the differential cell count. This study was conducted to estimate the value of bronchoalveolar lavage fluid (BALF) total cell count (TCC) in the diagnosis of ILD. We analyzed 237 BAL samples from patients with ILD: sarcoidosis (SA), idiopathic pulmonary fibrosis (IPF), cryptogenic organizing pneumonia (COP), hypersensitivity pneumonitis (HP), chronic eosinophilic pneumonia (CEP), and smoking-related ILD (sr-ILD). The control group consisted of 30 healthy volunteers. The statistical analysis revealed significant differences in the BALF TCC between healthy controls and patients with SA, IPF, HP, COP, sr-ILD, and eosinophilic disorders (mean values 6.9 vs. 14.5, 22.5, 22.8, 20.7, 64.5, and 27.3 × 10⁶, respectively). Logistic regression revealed a significant relation between the TCC and ILD diagnosis. We conclude that the TCC, as well as the value of total number of inflammatory cells, should be reported in the description of BAL.

Costabel, U., J. Guzman, F. Bonella, and S. Oshimo. 2007. Bronchoalveolar lavage in other interstitial lung diseases. Seminars in Respiratory and Critical Care Medicine 28: 514–524.PubMedCrossRef

Drent, M., K. Mansour, and C. Linssen. 2007. Bronchoalveolar lavage in sarcoidosis. Seminars in Respiratory and Critical Care Medicine 28: 486–495.PubMedCrossRef

Nagai, S., T. Handa, Y. Ito, M. Takeuchi, and T. Izumi. 2007. Bronchoalveolar lavage in idiopathic interstitial lung diseases. Seminars in Respiratory and Critical Care Medicine 28: 496–503.PubMedCrossRef

Poletti, V., G. Poletti, B. Murer, L. Saragoni, and M. Chilosi. 2007. Bronchoalveolar lavage in malignancy. Seminars in Respiratory and Critical Care Medicine 28: 534–545.PubMedCrossRef

American Thoracic Society. 2002. European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine 65: 277–304.

Bradley, B., H.M. Branley, J.J. Egan, M.S. Greaves, D.M. Hansell, N.K. Harrison, N. Hirani, R. Hubbard, F. Lake, A.B. Millar, W.A. Wallace, A.U. Wells, M.K. Whyte, and M.L. Wilsher. 2008. Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63(Suppl 5): v1–v58.PubMed

Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group: Eur Respir J 1989; 2:561–585

Baughman, R.P. 2007. Technical aspects of bronchoalveolar lavage: Recommendations for a standard procedure. Seminars in Respiratory and Critical Care Medicine 28: 475–485.PubMedCrossRef

Rennard, S.I., R. Aalbers, E. Bleecker, H. Klech, L. Rosenwasser, D. Olivieri, and Y. Sibille. 1998. Bronchoalveolar lavage: Performance, sampling procedure, processing and assessment. The European Respiratory Journal—Supplement 26: 13S–15S.PubMed

10.

Chcialowski, A., J. Chorostkowska-Wynimko, A. Fal, R. Pawlowicz, and J. Domagala-Kulawik. 2011. Recommendation of the Polish Respiratory Society for bronchoalveolar lavage (BAL) sampling, processing and analysis methods. Pneumonologia i Alergologia Polska 79: 75–98.PubMed

11.

Tabuena, R.P., S. Nagai, T. Tsutsumi, T. Handa, T. Minoru, T. Mikuniya, M. Shigematsu, K. Hamada, T. Izumi, and M. Mishima. 2005. Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese patients. Respiration 72: 490–498.PubMedCrossRef

12.

Katzenstein, A.L., S. Mukhopadhyay, and J.L. Myers. 2008. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Human Pathology 39: 1275–1294.PubMedCrossRef

13.

Schildge, J., C. Nagel, and C. Grun. 2007. Bronchoalveolar lavage in interstitial lung diseases: Does the recovery rate affect the results? Respiration 74: 553–557.PubMedCrossRef

14.

Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1990;141:S169–S202

15.

Costabel U. 1998. Atlas of Bronchoalveolar Lavage. Chapman and Hall Medical.

16.

Merchant, R.K., D.A. Schwartz, R.A. Helmers, C.S. Dayton, and G.W. Hunninghake. 1992. Bronchoalveolar lavage cellularity. The distribution in normal volunteers. American Review of Respiratory Disease 146: 448–453.PubMed

17.

Costabel, U., K.J. Bross, C. Reuter, K.H. Ruhle, and H. Matthys. 1986. Alterations in immunoregulatory T-cell subsets in cigarette smokers. A phenotypic analysis of bronchoalveolar and blood lymphocytes. Chest 90: 39–44.PubMedCrossRef

18.

Ramirez, P., M. Valencia, and A. Torres. 2007. Bronchoalveolar lavage to diagnose respiratory infections. Seminars in Respiratory and Critical Care Medicine 28: 525–533.PubMedCrossRef

19.

Spagnolo, P., L. Richeldi, and G. Raghu. 2009. The role of bronchoalveolar lavage cellular analysis in the diagnosis of interstitial lung diseases. European Respiratory Society Monograph 46 (Interstitial Lung Diseases): 36–46.

20.

Domagala-Kulawik, J. 2008. BAL in the diagnosis of smoking-related interstitial lung diseases: Review of literature and analysis of our experience. Diagnostic Cytopathology 36: 909–915.PubMedCrossRef

21.

Katzenstein, A.L., and J.L. Myers. 1998. Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification. American Journal of Respiratory and Critical Care Medicine 157: 1301–1315.PubMed

22.

Lensmar, C., G. Elmberger, P. Sandgren, C.M. Skold, and A. Eklund. 1998. Leukocyte counts and macrophage phenotypes in induced sputum and bronchoalveolar lavage fluid from normal subjects. European Respiratory Journal 12: 595–600.PubMedCrossRef

23.

Visscher, D.W., and J.L. Myers. 2006. Histologic spectrum of idiopathic interstitial pneumonias. Proceedings of the American Thoracic Society 3: 322–329.PubMedCrossRef

24.

Antoniou, K.M., D.M. Hansell, M.B. Rubens, K. Marten, S.R. Desai, N.M. Siafakas, A.G. Nicholson, R.M. du Bois, and A.U. Wells. 2008. Idiopathic pulmonary fibrosis: Outcome in relation to smoking status. American Journal of Respiratory and Critical Care Medicine 177: 190–194.PubMedCrossRef

25.

Steele, M.P., M.C. Speer, J.E. Loyd, K.K. Brown, A. Herron, S.H. Slifer, L.H. Burch, M.M. Wahidi, J.A. Phillips III, T.A. Sporn, H.P. McAdams, M.I. Schwarz, and D.A. Schwartz. 2005. Clinical and pathologic features of familial interstitial pneumonia. American Journal of Respiratory and Critical Care Medicine 172: 1146–1152.PubMedCrossRef

26.

Ohshimo, S., F. Bonella, A. Cui, M. Beume, N. Kohno, J. Guzman, and U. Costabel. 2009. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 179: 1043–1047.PubMedCrossRef

27.

Hoser, G., J. Kawiak, J. Domagala-Kulawik, P. Kopinski, and W. Droszcz. 1999. Flow cytometric evaluation of lymphocyte subpopulations in BALF of healthy smokers and nonsmokers. Folia Histochemica et Cytobiologica 37: 25–30.PubMed

28.

Erjefalt, J.S., L. Uller, M. Malm-Erjefalt, and C.G. Persson. 2004. Rapid and efficient clearance of airway tissue granulocytes through transepithelial migration. Thorax 59: 136–143.PubMedCrossRef

Title: Bronchoalveolar Lavage Total Cell Count in Interstitial Lung Diseases—Does It Matter?
Authors: Joanna Domagała-Kulawik
Tomasz Skirecki
Marta Maskey-Warzechowska
Hanna Grubek-Jaworska
Ryszarda Chazan
Publication date: 01-06-2012
Publisher: Springer US
Published in: Inflammation / Issue 3/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-011-9378-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

The Effect of Regular Colchicine Treatment on Biomarkers Related with Vascular Injury in Newly Diagnosed Patients with Familial Mediterranean Fever

Chlorophyll Revisited: Anti-inflammatory Activities of Chlorophyll a and Inhibition of Expression of TNF-α Gene by the Same

Regulation of Oxidative Stress in Patients with Kawasaki Disease

Proteasome Inhibition Prevents Development of Experimental Dermal Fibrosis

Acute Oxidative Stress Affects IL-8 and TNF-α Expression in IPEC-J2 Porcine Epithelial Cells

The Role of Rho/Rho-Kinase Pathway in the Expression of ICAM-1 by Linoleic Acid in Human Aortic Endothelial Cells

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials